Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Inclusion Criteria: * Participants must sign an approved informed consent form (ICF) * Histologically or cytologically confirmed epithelial ovarian/fallopian tube/primary peritoneal carcinoma * Patients had to have received a front-line, platinum/taxane based chemotherapy regimen * Patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer or progressed within six months of completing the most recent platinum-based chemotherapy * Participants must have received prior platinum-based chemotherapy for management of primary disease but must not have received more than 3 prior systemic cytotoxic regimens. * Patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area and increased Ca 125 * A \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment * Age 20-75 years old * Performance status (WHO) 0-2 * Life expectancy of at least three months * Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3) * Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl) Exclusion Criteria: * prior therapy with vinorelbine or gemcitabine * treatment with \> 2 cytotoxic regimens (including primary platinum and taxane chemotherapy) * Serious comorbidities (as determined by the investigator) such as, but not limited to, active congestive heart failure, recent myocardial infarction or active infection. * Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ). * Symptomatic central nervous system (CNS) metastasis. * Uncontrolled intestinal obstruction * Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational * Pregnant or nursing.